Showing results (151-160 of 219) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|July 23, 2013
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studySant Chawla, Robert Henshaw, Leanne Seeger, et al.
The Lancet. Oncology|November 10, 2019
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 studySant Chawla, Jean-Yves Blay, Piotr Rutkowski, et al.
The Oncologist|May 28, 2017
Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality TherapyJennifer L Pretz, Constance M Barysauskas, Suzanne George, et al.
Anticancer Research|June 17, 2009
Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordomaJoseph Schwab, Cristina Antonescu, Patrick Boland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated LiposarcomaMatthew Ingham, Shing Lee, Brian A Van Tine, et al.
Cancer|October 28, 2022
Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcomaSantiago A Lozano-Calderón, Jose Ignacio Albergo, Olivier Q Groot, et al.
Nature Communications|September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcomaJoonil Jung, Joon Sang Lee, Mark A Dickson, et al.
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 2014
Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculatureHae-June Lee, Changhwan Yoon, Do Joong Park, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Pageof 22